

# Nivolumab/Ipilimumab Combination Therapy for dMMR/MSI-H Metastatic Colorectal Cancer

An HCP Tool From the Immuno-Oncology Essentials Initiative

Approximately 5% or fewer of metastatic colorectal cancers (CRCs) have defective DNA mismatch repair (dMMR) systems caused either by sporadic or genetic DNA mutations. Defective dMMR cause cellular hypermutations and high microsatellite instability (MSI-H), which make the cancer cells susceptible to immune checkpoint inhibitors.

The combination of nivolumab (Opdivo®) and ipilimumab (Yervoy®) is approved in previously treated, defective DNA mismatch repair (dMMR)/microsatellite high (MSI-H) metastatic colorectal cancer. Nivolumab and ipilimumab each improve anticancer responses and patient survival by inhibiting molecules known as checkpoints to enhance the patient's immune response. Nivolumab inhibits the checkpoint known as programmed death receptor-1 (PD-1), and ipilimumab inhibits the checkpoint cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4).


Antitumor activity is improved with nivolumab/ipilimumab combination therapy as compared with either monotherapy, but the risk and severity of immune-related adverse events (irAEs) is also heightened.

This document is part of an overall HCP toolkit to assist providers in optimizing the management and side effect profile of multi-agent immunotherapy treatment for previously treated, metastatic dMMR/MSI-H colorectal patients.

# DRUG DOSAGE/ADMINISTRATION

- Obtain pretreatment laboratory tests (eg, adrenal function [ACTH], clinical chemistries, liver function tests, and thyroid function tests) prior to initiation of therapy. Clinical chemistries and liver function tests should be done before each cycle. Thyroid function tests should be done before Cycle 3 treatment, and every 6-12 weeks during nivolumab monotherapy
- Both nivolumab and ipilimumab are monoclonal antibodies administered via intravenous infusion, using separate intravenous lines
- Both nivolumab and ipilimumab are clear to opalescent, colorless to pale-yellow solutions. Their vials should be discarded if the solutions are cloudy, discolored, or contains extraneous particulate matter (other than a few translucent-to-white, proteinaceous particles)
- Neither ipilimumab nor nivolumab should be coadministered with each other or with other drugs through the same intravenous line
- When administered in combination with each other, nivolumab should be infused first, followed on the same day by ipilimumab, using separate infusion bags and in-line filters with pore sizes of 0.2 – 1.2 microns for each infusion
- Vials of nivolumab and ipilimumab should not be shaken
- The dosing schema for the induction and maintenance phases is shown below

## Nivolumab + Ipilimumab Regimen Dosing Schedule



# SIDE EFFECTS AND THEIR MANAGEMENT

Because nivolumab and ipilimumab are immunotherapies that work by enhancing the patient’s immune system, most adverse reactions associated with the combination are related to overactivity of the patient’s immune system (ie, immune-related adverse events [irAEs]). Various organ systems or tissues may be affected. Risk and severity of irAEs are relatively higher when nivolumab and ipilimumab are coadministered than when used as monotherapies. The irAEs associated with nivolumab/ipilimumab combination therapy also tend to have an earlier onset.

- Keys to toxicity management:
  - » Proactive assessment for early signs/symptoms of toxicity
  - » Prompt intervention
  - » IrAEs are typically managed with dose interruption and selective use of corticosteroids
  - » In rare instances, toxicity may be steroid refractory, and additional immunosuppressive agents may be necessary (infliximab, mycophenolate mofetil, cyclophosphamide, etc)
  - » Nivolumab/ipilimumab may be held or discontinued depending on severity and/or persistence of the irAE
  - » Referral to organ specialist should be considered
- IrAEs associated with nivolumab/ipilimumab combination therapy can be categorized as most common, less common but serious, and others that are easily overlooked
- Table 1 lists these irAEs and the corresponding Care Step Pathways in Appendix 1. Other adverse events associated with nivolumab/ipilimumab are shown in Appendix 2

**Table 1. List of Care Step Pathways for the management of immune-related AEs associated with nivolumab/ipilimumab therapy**

IrAEs category	Examples	Location
Most common	Skin toxicities (pruritus, rash, etc) Gastrointestinal toxicity—Diarrhea/colitis Thyroiditis Hepatic toxicities	Appendix 1
Less common but serious	Additional endocrinopathies <ul style="list-style-type: none"> <li>- Hypophysitis (pituitary)</li> <li>- Adrenal insufficiency</li> <li>- Diabetes</li> </ul> Pneumonitis	Appendix 1
Easily overlooked	Arthralgia/arthritis Mucositis/xerostomia Nephritis	Appendix 1

# CLINICAL PEARLS

- Nivolumab/ipilimumab-related irAEs may occur at any time, including after treatment completion or discontinuation. Continuing to monitor patients is critical
- It is important to monitor laboratory values at the start of treatment, periodically during treatment, and as indicated clinically. Laboratory values commonly monitored include: CBC w/ differential, creatinine, alkaline phosphatase, AST/ALT, bilirubin (direct/total), sodium, potassium, calcium, magnesium, thyroid function, and glucose. Please see individual irAE CSPs for more specific discussion of laboratory monitoring
- Patients sometimes experience signs/symptoms that they think are due to “flu” or a cold, but that actually represent an irAE or an infusion reaction
- Endocrinopathies often present with vague symptoms (fatigue, headache, and/or depression) that can easily be overlooked or initially misdiagnosed. Hypervigilance and follow-up is important on the part of both HCPs and patients
- Unlike other irAEs, endocrinopathies usually do not resolve and may require lifelong hormone replacement therapy
- IrAEs may become apparent upon tapering of corticosteroids, since they can be suppressed or masked by immunosuppressive therapy. Patients should be advised to be on the lookout for early signs of irAEs during the tapering period
- HCPs should encourage patients to carry information about their nivolumab/ipilimumab regimen with them at all times. This might be the Immunotherapy Wallet Card from the Oncology Nursing Society, the nivolumab- and ipilimumab-specific wallet cards, or at least emergency phone numbers and the side effects associated with the regimen. You may suggest they paperclip the wallet and insurance cards together so information about their regimen will be shared whenever they show their insurance card
- Advise patients to take pictures of any skin lesions for documentation

## QUESTIONS & ANSWERS

**Q:** Should an asymptomatic endocrinopathy be treated?

**A:** A transient period of asymptomatic hyperthyroidism can sometimes be observed with PD-1 monotherapy, but it is more commonly observed early in treatment with combination nivolumab/ipilimumab. This period is typically followed by hypothyroidism which can be clinically detectable and often requires permanent hormone replacement therapy.

**Q:** If a patient does not finish all 4 doses of induction, can they go on to receive maintenance nivolumab?

**A:** This decision is made on an individual basis. Some safety factors taken into consideration are: (1) the severity of immune related side effects; (2) the time it took for the side effects to resolve; and (3) the specific side effects that contributed to the truncation of induction. Oftentimes, patients have been able to successfully transition to maintenance nivolumab.

**Q:** How do I counsel my patients about immunizations?

**A:** That's a logical question, given that the checkpoint inhibitors alter the immune response. Advise your patients not to receive live vaccines (eg, measles, mumps, and rubella and the varicella vaccine [Zostavax<sup>®</sup>]) because they have not been evaluated in this setting. The use of attenuated vaccines has been and continues to be evaluated. Counsel patients to discuss all immunizations with the oncology team prior to administration so the benefits and risks can be weighed on an individual basis. For example, SHINGRIX<sup>®</sup>, approved in 2017, is an attenuated (non-live) varicella vaccine; its use should be discussed with the oncology team if a recommendation is being made for the patient to receive the injection series. Patients should be encouraged to get the inactivated influenza vaccine annually. The nasal spray flu vaccine is a live attenuated influenza vaccine and should not be administered to patients treated with immune checkpoint inhibitors.

Continue on next page

# QUESTIONS & ANSWERS

Continued

**Q:** Does the safety profile of nivolumab/ipilimumab differ when it is used in various tumor types?

**A:** Generally, the safety profile of nivolumab/ipilimumab is similar across tumor types. However, the context may be different—patients with different tumor types may have differing comorbidities or underlying organ dysfunction. For example, lung cancer patients may have underlying lung disease that will exacerbate shortness of breath associated with pneumonitis.

**Q:** Is it safe to give nivolumab/ipilimumab in a patient with metastatic colorectal cancer to the liver with elevated liver function tests?

**A:** Yes, as long as the liver function tests are not greater than 3 times the upper limit of normal at baseline. However, immune mediated hepatitis is possible on nivolumab/ipilimumab, and patients should have careful and routine monitoring of liver function tests.

**Q:** How is diarrhea from nivolumab/ipilimumab different from that associated with other standard therapies such as 5-FU or irinotecan?

**A:** Immune mediated colitis is a potentially serious toxicity of nivolumab/ipilimumab, presenting not only with diarrhea, but with blood and mucus, different than standard chemotherapy. Patients should be counseled to immediately report any new abdominal pain associated with blood, mucus and diarrhea to providers.

**Q:** Can nivolumab/ipilimumab cause or worsen peripheral neuropathy?

**A:** Immune mediated neuropathy is possible on nivolumab/ipilimumab, although this is a less commonly reported side effect. However, patients should remain observant to baseline neuropathy worsening with the use to nivolumab/ipilimumab.

**Q:** How are the skin toxicities such as rash different than rash seen with EGFR-inhibitors?

**A:** The immune mediated rash from nivolumab/ipilimumab is generally more puritic, erythematous, and distributed throughout the body without a pustular component, nor confined primarily to the face, scalp, and upper body, as seen with a EGFR-inhibitor-induced rash.

# PATIENT RESOURCES

## Financial Assistance

BMS Access Support

1 (800) 861-0048

<http://www.bmsaccesssupport.bmscustomerconnect.com/patient>

## Additional Information Resources

American Cancer Society

[www.cancer.org](http://www.cancer.org)

American Cancer Society Resource Section

[www.cancer.org/cancer/colon-rectal-cancer/treating/immunotherapy.html](http://www.cancer.org/cancer/colon-rectal-cancer/treating/immunotherapy.html)

CancerCare

[www.cancercare.org](http://www.cancercare.org)

Colorectal Cancer Alliance

[www.ccalliance.org](http://www.ccalliance.org)

National Cancer Institute

[www.cancer.gov](http://www.cancer.gov)

## ADDITIONAL RESOURCES

- André T, Lonardi S, Wong M, et al: Nivolumab + ipilimumab combination in patients with DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer: First report of the full cohort from CheckMate-142. “<https://meetinglibrary.asco.org/record/155742/abstract>” 2018 Gastrointestinal Cancers Symposium. Abstract 553. Presented January 20, 2018.
- Boutros C, Tarhini A, Routier E, et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. *Nat Rev Clin Oncol*. 2016;13:473-486.
- Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. *J Clin Oncol*. 2018;36:1-60.
- Dadu R, Zobniw C, Diab A. Managing adverse events with immune checkpoint agents. *Cancer J*. 2016;22:121-129.
- Food and Drug Administration & Bristol-Myers Squibb. Risk Evaluation and Mitigation Strategy (REMS) for ipilimumab (Yervoy); April 2018. Includes wallet card etc. Available at: <https://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM249435.pdf>
- Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. *JAMA Oncol*. 2016;2:1346-1353.
- Kumar V, Chaudhary N, Garg M, Floudas CS, Soni P, Chandra AB. Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy. *Front Pharmacol*. 2017;8:49. doi: 10.3389/fphar.2017.00049.
- Lenz H-J, Lonardi S, Zagonel V, et al: Nivolumab plus low-dose ipilimumab as first-line therapy in microsatellite instability-high/DNA mismatch repair deficient metastatic colorectal cancer: Clinical update. “<https://meetinglibrary.asco.org/record/181902/abstract>” 2020 Gastrointestinal Cancers Symposium. Abstract 11. Presented January 25, 2020.
- Madden KM, Hoffner B. Ipilimumab-based therapy: consensus statement from the faculty of the Melanoma Nursing Initiative on managing adverse events with ipilimumab monotherapy and combination therapy with nivolumab. *Clin J Oncol Nurs*. 2017;21(suppl):30-41.

Continue on next page



## ADDITIONAL RESOURCES

Continued

- National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Management of Immunotherapy-Related Toxicities. Version 1.2020: Featured updates to the NCCN Guidelines. *JNCCN*. 2020;18(3):230-241.
- Oncology Nursing Society (ONS). Immunotherapy Wallet Cards.  
<https://www.ons.org/clinical-practice-resources/immunotherapy-patient-wallet-card>
- Opdivo® [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2020. Available at:  
[http://packageinserts.bms.com/pi/pi\\_opdivo.pdf](http://packageinserts.bms.com/pi/pi_opdivo.pdf)
- Opdivo patient alert card (wallet card) and other resources.  
<http://www.opdivo.com/servlet/servlet.FileDownload?file=00P1Y00000v60IZUAY>
- Rubin KM. Managing immune-related adverse events to ipilimumab: a nurse's guide. *Clin J Oncol Nurs*. 2012;16:E69-E75.
- Villadolid J, Amin A. Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. *Transl Lung Cancer Res*. 2015;4:560-577.
- Yervoy® [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2020. Available at:  
[https://packageinserts.bms.com/pi/pi\\_yervoy.pdf](https://packageinserts.bms.com/pi/pi_yervoy.pdf)

Click here for downloadable action plans to customize for your patients

# APPENDIX 1

**The 12 Care Step Pathways (CSPs) referenced in this Appendix are housed in the CSP section of the AIMWithImmunotherapy.com IO Essentials website. These CSPs are currently universally applicable (i.e., they don't differ across tumor types).**

**Please click the link below to access the CSPs, which can also be printed from that section of the site.**

<http://aimwithimmunotherapy.org/care-step-pathways/>

# APPENDIX 2

## Management of other AEs associated with nivolumab/ipilimumab therapy.

Adverse event	Common symptoms	Common management/anticipatory guidance
Acute respiratory distress syndrome	Severe shortness of breath, dyspnea, or rapid breathing, hypotension, confusion, and extreme fatigue	<ul style="list-style-type: none"> <li>• Serious condition requiring hospitalization/expert care, including supplemental oxygen, often mechanical ventilation, and fluid management</li> </ul>
Anorexia	Decreased appetite	<ul style="list-style-type: none"> <li>• Monitor weight; query patient about appetite/eating habits; advise dietary modification if necessary (should improve with time)</li> <li>• Anticipate standard dose holds/discontinuations*</li> <li>• Consider referral to nutrition services for counseling on best food choices to avoid excessive weight loss</li> </ul>
Cardiotoxicity: cardiomyopathy, myocarditis, heart failure	Dyspnea, edema, fatigue, chest pain, arrhythmias, abdominal pain or ascites	<ul style="list-style-type: none"> <li>• Monitor weight, changes in breathing, extremity edema, chest/back/arm/jaw pain, pressure</li> <li>• ECG, Echo, stress test cardiology referral, 2 mg/kg prednisone, discontinue therapy</li> </ul>
Constipation/ abdominal pain (associated with nivolumab)	Infrequent stools/ difficulty stooling, abdominal pain	<ul style="list-style-type: none"> <li>• Increase fluid, fiber; use caution with use of laxatives</li> <li>• Consider appropriate testing to evaluate bowel obstruction</li> <li>• Anticipate standard nivolumab dose holds/discontinuations* for Grade 3 and Grade 4 (constipation with manual evacuation indicated, severe abdominal pain, or life-threatening consequences)</li> </ul>
Embryo-fetal toxicity	—	<ul style="list-style-type: none"> <li>• Advise of risk to fetus and recommend use of effective contraception during treatment and for 3 months after ipilimumab and for 5 months after nivolumab is discontinued</li> <li>• Advise patient to tell HCP immediately if they or their partner suspect they are pregnant while taking therapy</li> </ul>
Encephalitis	Headache, fever, tiredness, confusion, memory problems, sleepiness, hallucinations, seizures, stiff neck	<ul style="list-style-type: none"> <li>• New-onset (Grade 2-3) moderate to severe symptoms: rule out infectious or other causes; consult neurologist, obtain brain MRI and lumbar puncture</li> <li>• For ipilimumab: Anticipate standard ipilimumab dosage holds/discontinuations*; administer corticosteroids at dose of 1-2 mg/kg/d prednisone equivalents (or 2-4 mg/kg if necessary)</li> <li>• For nivolumab: Withhold nivolumab for new-onset moderate to severe neurologic symptoms; evaluate as described above; if other etiologies are ruled out, administer corticosteroids and permanently discontinue nivolumab for immune-mediated encephalitis</li> </ul>

Continue on next page

## Management of other AEs associated with nivolumab/ipilimumab therapy.

(Continued)

Adverse event	Common symptoms	Common management/anticipatory guidance
Fatigue	Feeling tired; lack of energy	<ul style="list-style-type: none"> <li>• Query patients regarding energy level; evaluate possible contributory factors, including infection, disease progression, and hematological and metabolic abnormalities; standard supportive care</li> <li>• Anticipate standard dose holds/discontinuations*</li> <li>• Fatigue that interferes with ADLs is concerning and should be evaluated for underlying causes, such as possible endocrinopathy</li> </ul>
Headache	Head pain	<ul style="list-style-type: none"> <li>• Need to rule out brain metastases, encephalitis, or hypophysitis; otherwise, standard supportive care (should improve with time)</li> <li>• Headache occurring in conjunction with fatigue could be indicative of hypophysitis</li> <li>• Anticipate standard dose holds/discontinuations*</li> </ul>
Infusion reaction	Chills/shaking, back pain, itching, flushing, difficulty breathing, hypotension, fever	<ul style="list-style-type: none"> <li>• For mild/moderate (Grade 1-2) reactions: interrupt or slow rate of infusion; monitor to recovery</li> <li>• For severe/life-threatening (Grade 3-4) reactions: Discontinue nivolumab and/or ipilimumab; manage anaphylaxis via institutional protocol; monitor. Premedication with an antipyretic and antihistamine may be considered for future doses</li> </ul>
Insomnia (associated with ipilimumab and corticosteroid therapy)	Difficulty falling or staying asleep	<ul style="list-style-type: none"> <li>• Counsel patients on good sleep habits; prescription medications can be used if needed (should improve over time)</li> <li>• Anticipate standard dose holds/discontinuations*</li> </ul>
Nausea/vomiting	Vomiting, queasiness, RUQ or LUQ pain	<ul style="list-style-type: none"> <li>• Provide standard supportive care, since it is adequate in most cases</li> <li>• Check LFTs/lipase/amylase if hepatotoxicity or pancreatitis is suspected</li> <li>• Anticipate standard dose holds/discontinuations</li> </ul>
Ocular: conjunctivitis, blepharitis, episcleritis, iritis, ocular myositis, scleritis, uveitis (associated with ipilimumab)	Blurry vision, double vision, or other vision problems, eye pain or redness	<ul style="list-style-type: none"> <li>• Test and evaluate for uveitis and episcleritis (by ophthalmologist, preferably)</li> <li>• Urgency of ophthalmology referral increases with grade</li> <li>• G1: continue immunotherapy, use artificial tears</li> <li>• G2: hold immunotherapy; ophthalmic and systemic CS (discontinue ipilimumab in patients not improving to G1 within 2 weeks on topical therapy or in those requiring systemic therapy)</li> <li>• G3 or G4: permanently discontinue immunotherapy; treatment by ophthalmologist to include ophthalmic and systemic CS</li> </ul>

Continue on next page

## Management of other AEs associated with nivolumab/ipilimumab therapy. (Continued)

Adverse event	Common symptoms	Common management/anticipatory guidance
Pyrexia	Elevated body temperature	<ul style="list-style-type: none"> <li>• Standard supportive care related to cytokine release</li> <li>• Consider infectious workup for prolonged elevated temperature</li> <li>• Anticipate standard dose holds/discontinuations*</li> </ul>
Rhabdomyolysis	Pain, muscle weakness, vomiting, confusion, tea-colored urine	<ul style="list-style-type: none"> <li>• Anticipate dose holds/discontinuations*</li> <li>• Intravenous fluids and corticosteroids (check creatine kinase levels)</li> </ul>
Upper respiratory tract infection	Cough, runny nose, sore throat, nasal breathing	<ul style="list-style-type: none"> <li>• Standard supportive care</li> <li>• Any cough needs to be evaluated for possible infection vs pneumonitis</li> <li>• Anticipate standard nivolumab treatment holds*</li> </ul>

### Dose holds/discontinuations

\*For nivolumab: Withhold for any Grade 3 (severe) AE. Permanently discontinue for any Grade 4 (life-threatening) AE, persistent Grade 2-3 AE, any severe (Grade 3) AE that recurs, or when  $\geq 10$  mg/d prednisone or equivalent is required for 12 weeks. Resume treatment when AE returns to Grade 0 or 1.

For ipilimumab: Withhold for any Grade 2 (moderate) AE, and resume treatment when AE returns to Grade 0 or 1; permanently discontinue for any Grade 3-4 (life-threatening) AE, persistent Grade 2 AE lasting  $\geq 6$  weeks, or inability to reduce corticosteroid dosage to 7.5 mg/d prednisone or equivalent.